FDA advisers question efficacy of Roche’s Polivy in first line LBCL
Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter
Merck KGaA makes its Foundry data tools available for free
eConsent in clinical trials: what’s new and what’s yet to come?
*please scroll down for all the latest news*
